ProCE Banner Activity


Therapeutic Strategies in Multiple Myeloma: Overview of Current and Emerging Treatment Options

Text Module

Review this expert analysis of current and emerging therapeutic strategies across multiple myeloma.

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Pharmacists: 1.00 contact hour (0.1 CEUs)

Nurses: 1.00 Nursing contact hour

Released: April 26, 2023

Expiration: April 25, 2024



Shaji K. Kumar

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Chair, Myeloma Amyloidosis Dysproteinemia Group
Consultant, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Provided by

Provided by Clinical Care Options, LLC in partnership with Smart Patients

ProCE Banner


Supported by educational grants from AbbVie, Bristol-Myers Squibb, GlaxoSmithKline, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Karyopharm Therapeutics and Regeneron Pharmaceuticals, Inc.


Bristol Myers Squibb


Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Karyopharm Therapeutics

Regeneron Pharmaceuticals, Inc.


Smart Patients

ProCE Banner

Target Audience

This educational program is intended for hematologists, oncologists, nurses, pharmacists, and other healthcare professionals who care for patients with multiple myeloma. This educational program is also intended to reach patients with multiple myeloma and their caregivers.

Program Learning Goal

The goal of this activity is to educate hematologists, oncologists, oncology nurses, pharmacists, other healthcare professionals, and patients about recent developments in the treatment of multiple myeloma to optimally individualize therapy.

Learning Objectives

After completing this activity, participants should be better able to:

  • Initiate timely systemic treatment for appropriate patients based on the latest multiple myeloma diagnosis and staging criteria

  • Select optimal initial individualized therapy for patients with newly diagnosed multiple myeloma through consideration of the available clinical data, risk assessment, and comorbidities, along with patient medical history and preferences

  • Plan appropriate consolidation or maintenance therapy approaches for patients with multiple myeloma

  • Devise therapeutic strategies with new and emerging agents and novel combination regimens for patients with relapsed/refractory multiple myeloma based on available data, expert recommendations, and individual patient and disease characteristics

  • Evaluate strategies to address racial and age-related disparities in the care of patients with multiple myeloma, including incidence, age, stage at diagnosis, access to care, treatment, and clinical outcomes

  • Identify patients who may be eligible to enroll on a clinical trial of investigational therapies or combination regimens to treat multiple myeloma at all stages of the disease


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Chair, Myeloma Amyloidosis Dysproteinemia Group
Consultant, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Shaji K. Kumar, MD: consultant/advisor (paid to institution): K36, AbbVie, Amgen, Antengene, ArcellX, AstraZeneca, BeiGene, Bluebird Bio, Bristol-Myers Squibb, Janssen, Loxo Oncology, Oncopeptides, Roche/Genentech, Sanofi; consultant/advisor: Secura Biotherapeutics, Takeda, Trillium; researcher (paid to institution): AbbVie, Allogene, Amgen, AstraZeneca, Bristol-Myers Squibb, Carsgen, GlaxoSmithKline, Janssen, Novartis, Roche/Genentech, Regeneron, Takeda.

The planners and content peer reviewers from Clinical Care Options, LLC and Smart Patients do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hour. To successfully complete this activity and receive credit, learners must follow these steps during the period from April 26, 2023, through April 25, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page
  2. Read the target audience, learning objectives, and faculty disclosures
  3. View and study the content in its entirety
  4. Submit answers to the post-test questions and evaluation questions online

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by clicking the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.


This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.00 contact hours.

Continuing Pharmacy Education
CCO designates this continuing education activity for 1.00 contact hours (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-23-118-H01-P

Type of Activity: Application

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.